Navigation Links
Amylin Pharmaceuticals to Present at Thomas Weisel Healthcare, BioCentury NewsMakers, and Morgan Stanley Global Healthcare Conferences
Date:8/28/2008

SAN DIEGO, Aug. 28 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) will be presenting at the Thomas Weisel Healthcare Conference in Boston on Wednesday, September 3, 2008 at 9:10 a.m. ET, at the BioCentury NewsMakers Conference in New York on Thursday, September 4, 2008 at 11:30 a.m. ET, and at the Morgan Stanley Global Healthcare Unplugged Conference in New York on Tuesday, September 9, 2008 at 10:55 a.m. ET. Mark G. Foletta, Amylin's Senior Vice President of Finance and Chief Financial Officer, will be providing corporate overviews at Thomas Weisel and BioCentury. Daniel M. Bradbury, Amylin's President and Chief Executive Officer, will be providing a corporate overview at Morgan Stanley.

The live presentations will be Web cast, and recordings will be made available following the event. The Web casts and recordings will be accessible through Amylin's corporate Web site, located at http://www.amylin.com. To access the live Web casts, please log on to Amylin's site approximately fifteen minutes prior to the presentations to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company committed to improving lives through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN(R) (pramlintide acetate) injection and BYETTA(R) (exenatide) injection. Amylin's research and development activities leverage the company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California with over 2,000 empl
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Amylin Pharmaceuticals to Present at BioCentury NewsMakers Conference, Thomas Weisel Healthcare Conference and Bear Stearns Healthcare Conference
2. Drs. John Patton of Nektar, Igor Gonda of Aradigm, Tomas Landh of Novo Nordisk, Chris Rhodes of Amylin to Speak at iiBIGs Plenary Panel in Vegas
3. Amylin Pharmaceuticals Reports Third Quarter Financial Results
4. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
5. Amylin Pharmaceuticals Elects Adrian Adams to Board of Directors
6. Xenome Receives a Syndicated US$10 Million Equity Investment from Queensland BioCapital Fund, Amylin Pharmaceuticals and Innovis Investment Partners
7. Amylin Pharmaceuticals to Present at Nasdaq 20th Investor Program
8. Amylin Pharmaceuticals to Present at Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
9. Amylin Pharmaceuticals to Webcast First Quarter Results
10. Amylin Pharmaceuticals to Present at Morgan Stanley Global Healthcare Unplugged Conference
11. Amylin Pharmaceuticals Announces Time Change to Previously Announced Presentation at the Morgan Stanley Global Healthcare Unplugged Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
... Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that ... Cancer Care , a national support services organization for people ... educational programs for people facing lung and ovarian cancers.  The ... their families become aware of options available to help treat ...
... graphite particles 1000 times smaller than the width of a ... boost the efficiencyand profitabilityof solar power plants. Photovoltaic (PV) ... but they,re not necessarily the best solar power solution. "The ... only a fraction of the sunlight that hits them, and ...
... PARIS, April 5, 2011 Cellectis (Alternext: ALCLS), the genome ... signed an agreement with the Caisse des Depots (a French ... in two steps, reserved in equal parts to Cellectis and ... later than January 31, 2012, and is subject to the ...
Cached Biology Technology:Morphotek®, Inc. Receives Beacon Award From CancerCare 2Morphotek®, Inc. Receives Beacon Award From CancerCare 3Nanoparticles improve solar collection efficiency 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 2Cellectis and Caisse des Depots Sign Agreement on a Project for the Industrial Development of iPS Cells 3
(Date:12/17/2014)... NEW YORK , Dec. 15, 2014 /PRNewswire-USNewswire/ ... a Good Clinical Practices (GCP) audit to confirm ... Administration (FDA) regulations. This accomplishment enables HITLAB to ... trials utilizing the highest principles for patient safety ... to improve global healthcare access, quality, and delivery ...
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/twhjll/biometrics_market ) has announced the addition of ... 2015-2019"  report to their offering. ... advances in technology. With continuous advances in technology, ... the latest standard that meets the needs and ...
(Date:12/10/2014)...  Valencell, a leader in performance biometric data sensor ... from its licensees for highly accurate, clinically validated biometric ... coming from fitness and health sectors, but first responders/military ... is only as useful as the biometric data it ... in long-term mass consumer adoption of wearable products," said ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Biometrics Market in the APAC Region 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... GAINESVILLE, Fla. New University of Florida research puts to ... the last glacial period. It turns out it ended up ... The findings have implications for modern-day global warming, said ... of the paper, which is published in this week,s journal ...
... team of researchers based at the Institute of Vertebrate ... professor at Washington University in St. Louis, has discovered ... anthropologists perceptions of the emergence of modern humans in ... published Oct. 25 in the online early edition of ...
... HOUSTON, Oct. 25, 2010 Some unexpected effects ... and reverse blindness have been uncovered by a University ... Donald A. Fox, a professor of vision sciences ... findings in a paper titled "Low-Level Gestational Lead Exposure ...
Cached Biology News:UF research gives clues about carbon dioxide patterns at end of Ice Age 2UF research gives clues about carbon dioxide patterns at end of Ice Age 3Unexpected findings of lead exposure may lead to treating blindness 2Unexpected findings of lead exposure may lead to treating blindness 3
... T2-04 is an ultra-compact pump available in single ... and ideal for use in portable air and ... this pump works well in environments where DC ... compact size are critical., Offers ultra-compact size, ...
Curcumin is an extract of turmeric root with antioxidant, anti-tumor promoter, and anti-inflammatory properties. Curcumin inhibits the induction of NOS in macrophages....
Total Proteins from over 50 different human Alzheimer, Diabetic, Liver Cirrhosis, and Lupus diseased tissues are available....
... Lone Wolf valve has the highest performance ... available on the market. This VSO valve ... and ensures maximum accuracy., Achieves rapid, ... and patient comfort. , Maintains ideal flow ...
Biology Products: